Addressing Unmet Medical Needs

Addressing Serious Unmet Medical Needs

Cancer is the second most common cause of death in the United States. Historically, cancer treatment has been limited to surgical removal, cytotoxic chemotherapy and/or radiation, providing incremental benefit.


Targeted therapies specifically interdict a single cellular pathway which may lead to favorable clinical responses in some patients. Unfortunately, many patients are either not eligible for targeted therapy or relapse after responding to initial treatment.


Immunotherapy comprises several different modalities. Each one activates the immune system by attacking specific genetic changes in individual tumors and redirecting the patient’s immune system to eliminate tumors.

nurse comforting cancer patient

Differentiated Potential

Potential utility against a broad range of tumor types and metastatic disease

Physician-preferred/familiar administration

      • Local, regional or systemic routes of delivery
      • “Off-the-shelf” therapeutic


Advanced, non-local delivery oncolytic virus clinical program

Ovarian Cancer Program

      • Actively recruiting patients for Phase 3 OnPrime registration trial in platinum-resistant/refractory ovarian cancer (PRROC)
      • Met preestablished endpoint of our Phase 2 VIRO-15 trial in PRROC


Systemic Delivery Program

      • Actively preparing to initiate a Phase 2 trial in recurrent non-small cell lung cancer
      • Promising early clinical trials in solid tumors demonstrate feasibility of systemic administration


Mechanism of Action

Antitumor activity with demonstrated activity as monotherapy and combination therapy

      • Boosts patient’s own immune system to turn “cold” tumors “hot”
      • Sensitizes (re-sensitizes) resistant tumors to chemotherapy (platinum)


Robust pipeline

      • Second generation product candidates offer multiple ”shots on goal”
      • Active IND in pancreatic cancer for V2ACT Immunotherapy, a novel immuno-oncology modality held by our joint venture, V2ACT Therapeutics LLC; initiation of clinical trial not yet scheduled.
      • 500+ novel strains generated via proprietary CHOICE™ platform



Attractive cost-of-goods

      • Company-controlled GMP manufacturing facility in San Diego
      • Proprietary large-scale cGMP manufacturing process